SMAD4 Antibody

Immunohistochemistry (FFPE): 1-2ug/ml

Optimal dilution of the recombinant SMAD4 antibody should be determined by the researcher.

Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80% of cases of pancreatic adenocarcinoma, but rarely in endometrial (0%), colorectal (0%), ovarian (3%), lung (0%), breast (2%) adenocarcinomas, and malignant melanoma (4%). SMAD4is an important marker for confirming a diagnosis of pancreatic adenocarcinoma.

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

Recombinant human full-length SMAD4 protein (amino acids 1-552) was used as the immunogen for the recombinant SMAD4 antibody.

This recombinant SMAD4 antibody is available for research use only.

Nucleus, Cytoplasm

Protein A/G affinity

Q13485